安络化纤丸联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效

Clinical Effcacy of Anluohuaxian Pill Combined with Entecavir in the Treatment of Chronic Hepatitis B Liver Fibrosis

为探讨安络化纤丸联合恩替卡韦治疗慢性乙型肝炎纤维化的临床疗效,在成都市公共卫生临床医疗中心收治的慢性乙型肝炎肝纤维化患者中,选取2020年2月—2022年2月时间段入院的72例作为研究对象。遵循随机分组的原则,将选取的患者划分为对照组(n=36)和观察组(n=36),前者实施恩替卡韦治疗,后者实施安络化纤丸联合恩替卡韦治疗。持续给药12周。在治疗前、治疗后,对患者的肝功能指标进行检测、统计,且就患者的相关指标转阴率和不良反应发生状况加以记录。研究发现,治疗前,对患者的肝功能指标进行比较,P>0.05,无差异,具体指标为AST(天冬氨酸氨基转移酶)、TBiL(总胆红素)、ALT(丙氨酸氨基转移酶)、肝脏硬度值、Chil-Pugh评分。而在治疗后,观察组这几项指标相较于对照组偏低,差异显著(P<0.05)。在HBV-DNA转阴率、HBeAg(乙肝e抗原)转阴率上,观察组明显高于对照组,差异显著(P<0.05)。用药期间,两组均有患者出现不良反应,相对轻微,P>0.05。由此可见,对患有慢性乙型肝炎纤维化的病人,给予安络化纤丸联合恩替卡韦进行治疗,可对患者的肝脏指标进行改善,促进肝功能恢复,使得相关指标转阴,且不良反应轻微,安全性良好,值得临床选用。

In order to explore the clinical efficacy of anluohuaxian pill combined with entecavir in the treatment of chronic hepatitis Bfibrosis,72 patients with chronic hepatitis B liverfibrosis admitted from February 2020 to February 2022 were selected as the subjects of this study.According to the principle of randomization,the selected patients were divided into control group(n=36)and observation group(n=36).The former was treated with entecavir,and the latter was treated with anluohuaxian pill combined with entecavir.The drug was administered continuously for 12 weeks.Before and after treatment,the liver function indexes of the patients were detected and counted,and the negative conversion rate of relevant indexes and the occurrence of adverse reactions were recorded.The study found that before treatment,the liver function indexes of the patients were compared(P>0.05),and there was no difference.The specific indexes were ast(aspartate aminotransferase),TBIL(total bilirubin),ALT(alanine aminotransferase),liver hardness value and chil Pugh score.After treatment,these indexes in the observation group were lower than those in the control group(P<0.05).The negative rate of HBV-DNA and HBeAg(hepatitis B e antigen)in the observation group was significantly higher than that in the control group(P<0.05).During the medication period,both groups had relatively mild adverse reactions(P>0.05).It can be seen that the treatment of anluohuaxian pill combined with entecavir can improve the liver indexes of patients with chronic hepatitis Bfibrosis,promote the recovery of liver function,and make the relevant indexes turn negative,with mild adverse reactions and good safety.It is worthy of clinical selection.